Skip to content
Clinical Trials – home

Terbinafine: An Antifungal Medication for Treating Fungal Infections

1 / 2
trials open to patients / all trials
5+
Countries

In short

This article examines the use of terbinafine, an antifungal medication, in various clinical trials. Terbinafine has been studied for treating conditions like onychomycosis (nail fungus), tinea pedis (athlete's foot), and tinea capitis (scalp ringworm). The trials investigate different formulations, including oral tablets, topical creams, nail lacquers, and film-forming solutions. Researchers aim to assess the drug's effectiveness, safety, and optimal treatment durations for these fungal infections.

At a glance

Formulations studied
Oral tablets, topical creams, nail lacquers, film-forming solutions
Conditions treated
Onychomycosis, tinea pedis, tinea capitis
Treatment durations
Single application to 48 weeks, depending on condition and formulation
Primary outcomes
Complete cure, mycological cure, clinical effectiveness
Safety assessments
Adverse events, tolerability, laboratory tests
Study designs
Randomized, double-blind, placebo-controlled, multicenter trials
Special populations
Adults and children (age-dependent on trial)
Comparators
Placebo, vehicle control, active comparators (e.g., other antifungal products)

What is Terbinafine?

Terbinafine is an antifungal medication used to treat various fungal infections. It belongs to a class of drugs called allylamine antifungals. Terbinafine is available under the brand name Lamisil, as well as in generic forms. This medication works by stopping the growth of fungi that cause infections.

What Conditions Does Terbinafine Treat?

Terbinafine is used to treat several types of fungal infections, including:

  • Onychomycosis: A fungal infection of the toenails or fingernails, also known as nail fungus
  • Tinea pedis: A fungal infection of the feet, commonly known as athlete's foot
  • Tinea capitis: A fungal infection of the scalp, which primarily affects children

These fungal infections are caused by various types of fungi, including dermatophytes such as Trichophyton, Microsporum, and Epidermophyton species.

How Does Terbinafine Work?

Terbinafine works by interfering with the fungal cell membrane formation. It does this by blocking an enzyme called squalene epoxidase, which is essential for fungal growth. By inhibiting this enzyme, terbinafine prevents the fungi from producing a substance called ergosterol, which is crucial for their cell membranes. This action ultimately leads to the death of the fungal cells, helping to clear the infection.

Forms and Dosages of Terbinafine

Terbinafine is available in several forms, including:

  • Oral tablets: Usually 250 mg, taken once daily for a specified period depending on the type and severity of the infection
  • Topical creams or solutions: Applied directly to the affected area, typically once or twice daily
  • Nail lacquer: A special formulation designed to be applied directly to infected nails

The dosage and duration of treatment can vary depending on the specific condition being treated and the patient's age and weight. For example, in children with tinea capitis, the dosage is often based on body weight: 25 kg for 125 mg, 25-35 kg for 187.5 mg, and over 35 kg for 250 mg.

Effectiveness of Terbinafine

Clinical trials have shown terbinafine to be effective in treating various fungal infections. For example:

  • In onychomycosis (nail fungus), terbinafine has shown effectiveness in achieving complete cure, which is defined as negative microscopy, negative culture for dermatophytes, and no residual involvement of the target toenail.
  • For tinea pedis (athlete's foot), studies have evaluated the effectiveness of terbinafine in achieving both mycological cure (negative microscopy and culture) and clinical improvement of symptoms.
  • In tinea capitis (scalp fungal infection), terbinafine has been shown to be effective, although some cases of resistance have been reported.

Potential Side Effects

Like all medications, terbinafine can cause side effects. Common side effects may include:

  • Gastrointestinal disturbances (e.g., nausea, diarrhea)
  • Headache
  • Skin rashes or itching
  • Changes in taste sensation

More serious side effects are rare but can occur. These may include liver problems or severe skin reactions. It's important to discuss potential side effects with your healthcare provider and report any unusual symptoms during treatment.

Ongoing Research on Terbinafine

Research on terbinafine continues to explore its effectiveness in various formulations and treatment durations. Some areas of ongoing research include:

  • Evaluating the efficacy of single-application terbinafine solutions for tinea pedis
  • Investigating the effectiveness of terbinafine nail lacquers for treating onychomycosis with different treatment durations (24 vs 48 weeks)
  • Studying the pharmacokinetics (how the drug moves through the body) of different terbinafine formulations
  • Examining potential antifungal resistance in tinea capitis cases

These ongoing studies aim to improve treatment outcomes and find the most effective ways to use terbinafine for various fungal infections.

Questions people often ask

Conditions where Terbinafine is being studied

Each condition opens its own overview and trial list

Trials with Terbinafine

Recruiting trials first

See all 2 →
Quick filters
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).